Wang Gengshen, Chen Jiuyi, Ma Ruofei, Xu Weiyuan, Yan Chunlu, Niu Cunliang
Department of Orthopaedics, Wuwei People's Hospital, Wuwei, Gansu 733000, P.R. China.
Department of Respiratory Medicine, Wuwei People's Hospital, Wuwei, Gansu 733000, P.R. China.
Oncol Lett. 2018 Aug;16(2):1696-1700. doi: 10.3892/ol.2018.8804. Epub 2018 May 24.
The aim of the study was to investigate the efficiency and safety of zoledronic acid and ibandronate in the treatment of rats with lung cancer combined with bone metastases. A total of 124 rats with lung cancer bone metastasis were established. Rats were randomly divided into A, B and C groups (n=30). Rats in group A were treated with ibandronate combined with zoledronic acid, rats in group B were treated with zoledronic acid monotherapy, and rats in group C were treated with ibandronate monotherapy. Rats in group A were injected subcutaneously with zoledronic acid 0.1 mg/kg and ibandronate 10 µg/kg, once per week for 12 weeks; rats in group B were injected subcutaneously with zoledronic acid, and rats in group C were injected subcutaneously with ibandronate, the same method as the treatment group. The remaining 34 SD rats were not treated to serve as the control group. Treatment efficacy and physical improvement in 8 weeks were observed, and improvement of pain behavior in rats was evaluated to reflect the effect of drug treatment. Of the 30 rats in group A, 25 showed different degrees of remission, 5 rats showed no improvement and the effective rate was 83.3%. Of the 30 rats in group B, 21 showed different degrees of remission, 9 rats showed no improvement and the effective rate was 70%. Of the 30 rats in group C, 20 showed different degrees of remission, 10 rats showed no improvement and the effective rate was 66.7%. Statistically significant differences in total effective rate were found among three groups, and the combined method showed the highest effective rate (P<0.05). Ibandronate combined with zoledronic acid has a good therapeutic effect on cancer pain caused by bone metastases from lung cancer.
本研究的目的是探讨唑来膦酸和伊班膦酸钠治疗肺癌合并骨转移大鼠的有效性和安全性。共建立了124只肺癌骨转移大鼠模型。大鼠随机分为A、B、C组（n = 30）。A组大鼠接受伊班膦酸钠联合唑来膦酸治疗，B组大鼠接受唑来膦酸单药治疗，C组大鼠接受伊班膦酸钠单药治疗。A组大鼠皮下注射唑来膦酸0.1 mg/kg和伊班膦酸钠10 μg/kg，每周1次，共12周；B组大鼠皮下注射唑来膦酸，C组大鼠皮下注射伊班膦酸钠，给药方法同治疗组。其余34只SD大鼠未接受治疗作为对照组。观察8周时的治疗效果和身体改善情况，并评估大鼠疼痛行为的改善以反映药物治疗效果。A组30只大鼠中，25只显示不同程度的缓解，5只无改善，有效率为83.3%。B组30只大鼠中，21只显示不同程度的缓解，9只无改善，有效率为70%。C组30只大鼠中，20只显示不同程度的缓解，10只无改善，有效率为66.7%。三组总有效率差异有统计学意义，联合用药方法有效率最高（P<0.05）。伊班膦酸钠联合唑来膦酸对肺癌骨转移所致癌痛有良好的治疗效果。
